Wang S L, Lee J J, Liao A T
National Taiwan University Veterinary Hospital, College of Bioresources and Agriculture, National Taiwan University, Taipei, 10672, Taiwan; Department and Graduate Institute of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, 10617, Taiwan.
Graduate Institute of Veterinary Clinical Science, School of Veterinary Medicine, National Taiwan University, Taipei, 10617, Taiwan; Animal Cancer Center, College of Bioresources and Agriculture, National Taiwan University, Taipei, 10617, Taiwan.
Vet J. 2015 Jul;205(1):69-73. doi: 10.1016/j.tvjl.2015.04.032. Epub 2015 Apr 28.
Myelosuppression is one of the most common side effects of chemotherapy. The aim of this study was to determine whether chemotherapy-induced neutropenia is a positive prognostic indicator for remission and survival time in dogs with lymphoma. Fifty dogs with multicentric lymphoma received CHOP-based (C-cyclophosphamide; H-hydroxydaunorubicin; O-vincristine; P-prednisolone) chemotherapy using conventional dosages. Complete blood counts were recorded to determine the presence or absence of neutropenia after treatment. Toxicity, remission, and survival times were recorded and analysed. Thirteen dogs had chemotherapy-induced neutropenia and 37 had no neutropenia during the study period. No statistical difference was found between the groups for signalment or the presence of historical negative prognostic factors, except for bodyweight (P = 0.02). The median first remission times in the neutropenia and no neutropenia groups were 812 and 219 days, respectively (P <0.01). The median survival times of dogs in the neutropenia and no neutropenia groups were 952 and 282 days, respectively (P <0.01). Dogs with lymphoma that had chemotherapy-induced neutropenia exhibited significantly increased remission and survival times compared with dogs without neutropenia. Chemotherapeutic dosages may be adjusted individually to induce neutropenia without severe adverse effects in order to achieve longer remission and survival times.
骨髓抑制是化疗最常见的副作用之一。本研究的目的是确定化疗诱导的中性粒细胞减少是否是淋巴瘤犬缓解和生存时间的阳性预后指标。五十只患有多中心淋巴瘤的犬接受了基于CHOP方案（C-环磷酰胺；H-羟基柔红霉素；O-长春新碱；P-泼尼松龙）的常规剂量化疗。记录全血细胞计数以确定治疗后是否存在中性粒细胞减少。记录并分析毒性、缓解和生存时间。在研究期间，13只犬出现化疗诱导的中性粒细胞减少，37只未出现中性粒细胞减少。除体重外（P = 0.02），两组在体征或历史阴性预后因素的存在方面未发现统计学差异。中性粒细胞减少组和非中性粒细胞减少组的首次缓解时间中位数分别为812天和219天（P <0.01）。中性粒细胞减少组和非中性粒细胞减少组犬的生存时间中位数分别为952天和282天（P <0.01）。与未出现中性粒细胞减少的犬相比，出现化疗诱导的中性粒细胞减少的淋巴瘤犬的缓解和生存时间显著延长。可以单独调整化疗剂量以诱导中性粒细胞减少而无严重不良反应，从而实现更长的缓解和生存时间。
Zotero 插件